DIA: Driving Insights to Action
Science:Life Sciences
Niklas Hedberg, Chief Pharmacist for the Dental and Pharmaceuticals Benefits Agency in Sweden, chairs the executive board for the European Network for Health Technology Assessment known as EUnetHTA. “We typically see that there are a lot of comparative questions that are not or even cannot be answered by traditional randomized control trials,” he explains. “Anything that is outside the typical randomized controlled trial scope is probably going to be of increasing importance for the relative effectiveness and relative cost evaluation.” Mr. Hedberg hosted the EUnetHTA Town Hall at DIA Europe 2019.
GPP Experts Explain Authorship Algorithm
"Dossier in the Cloud" Democratizing Global Access
DIA: A Place Where You Can Make a Difference
Autumn’s Leukemia Story: Regimens, Recovery, and Realizations
Retiring TGA Head Maps Australia’s Post-Pandemic Future
Patient Engagement: Evolution of Who Knows What, Part 2
Patient Engagement: Evolution of Who Knows What, Part 1
Australian Clinical Trials Alliance Part 2 – Future Projections
ANVISA Explains Innovative Online Optimized Assessment Project
Australian Clinical Trials Alliance Part 1 – Current Perceptions
Looking Back and Ahead: Translational Science Advances Impacting Patient Care
Rwanda Welcomes African Medicines Agency Home
Will Technology Solve the Research “People Problem”?
Why Trans/Nonbinary Research Benefits All Communities
Digital Revolutionizing Data-Driven Reimbursement
China Sets New Record for Local Drug Approvals in 2021
WHO Pilot Formalizes CSA Process to Assist Developers
Medication Errors Emerge as Global Patient Safety Issue
What We Are Missing by Not Including ”Who?”
Cancer Data Ecosystem Powering Moonshot Relaunch
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Terrace | تراس